Source: VIVO Cannabis Inc.
  • VIVO Cannabis (VIVO) subsidiary Canna Farms has received a research licence from Health Canada
  • The license allows Canna Farms to evaluate its medical cannabis products
  • Through its Canna Farms and ABcann business units, VIVO Cannabis holds production and sales licences from Health Canada
  • VIVO Cannabis Inc. (VIVO) opened trading at C$0.05

VIVO Cannabis (VIVO) subsidiary Canna Farms has received a research licence from Health Canada.

The license allows Canna Farms to evaluate its medical cannabis products based on taste, smell, feel and visual appeal.

Ray Laflamme, Canna Farms’ Co-Founder and VIVO’s Chief Executive Officer, commented on the news.

“We are continually enhancing our product quality for our patients who rely on cannabis as medication. This licence allows us to understand the sensory characteristics of our cultivars in various product formats, and offers a competitive advantage for the new products and genetics we bring to market.”

Through its Canna Farms and ABcann business units, VIVO Cannabis holds production and sales licences from Health Canada and operates world-class indoor cultivation facilities. VIVO has a collection of premium brands including Canna Farms, Beacon Medical, Fireside, and Lumina. 

VIVO Cannabis Inc. (VIVO) opened trading at C$0.05.


More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.